Sabrina Viktoria Kirchleitner- Doctor of Medicine
- Neurosurgery Resident at Ludwig-Maximilians-Universität in Munich
Sabrina Viktoria Kirchleitner
- Doctor of Medicine
- Neurosurgery Resident at Ludwig-Maximilians-Universität in Munich
About
51
Publications
6,815
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
361
Citations
Introduction
experimental neurosurgery
Current institution
Additional affiliations
May 2024 - present
Publications
Publications (51)
Purpose
Current therapy strategies still provide only limited success in the treatment of glioblastoma, the most frequent primary brain tumor in adults. In addition to the characterization of the tumor microenvironment, global changes in the brain of patients with glioblastoma have been described. However, the impact and molecular signature of neur...
Purpose
This study investigates the outcomes of microsurgical resection of multiple brain metastasis (BMs).
Methods
This retrospective, monocentric analysis included clinical data from all consecutive BM patients, who underwent simultaneous resection of ≥ 2 BMs between January 2018 and May 2023. Postoperative neurological and functional outcomes,...
Local therapy strategies still provide only limited success in the treatment of glioblastoma, the most frequent primary brain tumor in adults, indicating global involvement of the brain in this fatal disease. To study the impact of neuroinflammation distant of the primary tumor site on the clinical course of patients with glioblastoma, we performed...
Background
Patients with intracranial meningiomas frequently suffer from tumor-related seizures prior to resection, impacting patients’ quality of life. We aimed to elaborate on incidence and predictors for seizures in a patient cohort with meningiomas WHO grade 2 and 3.
Methods
We retrospectively searched for patients with meningioma WHO grade 2...
![Comparison of [¹⁸F]GE-180 and [¹⁸F]FET uptake in GL261-implanted mice....](publication/377407028/figure/fig1/AS:11431281220328506@1706365300181/Comparison-of-FGE-180-and-FFET-uptake-in-GL261-implanted-mice-A-Coronal-H-E_Q320.jpg)
![[¹⁸F]GE-180 PETs in sham mice. (A) On the left, VOIRH_top (green),...](publication/377407028/figure/fig2/AS:11431281220328507@1706365301279/FGE-180-PETs-in-sham-mice-A-On-the-left-VOIRH-top-green-VOIRH-bottom-blue_Q320.jpg)
![[¹⁸F]GE-180 autoradiographies (ARGs) in sham mice. (A) Representative...](publication/377407028/figure/fig3/AS:11431281220328508@1706365301850/FGE-180-autoradiographies-ARGs-in-sham-mice-A-Representative-ARGs-at-different_Q320.jpg)
![Increased uptake along the biopsy trajectory in a human [¹⁸F]GE-180...](publication/377407028/figure/fig5/AS:11431281220328509@1706365303335/Increased-uptake-along-the-biopsy-trajectory-in-a-human-FGE-180-PET-Transversal-view_Q320.jpg)
Background: The translocator protein (TSPO) has been proven to have great potential as a target for the positron emission tomography (PET) imaging of glioblastoma. However, there is an ongoing debate about the potential various sources of the TSPO PET signal. This work investigates the impact of the inoculation-driven immune response on the PET sig...
Various cellular sources hamper interpretation of positron emission tomography (PET) biomarkers in the tumor microenvironment (TME). We developed an approach of immunomagnetic cell sorting after in vivo radiotracer injection (scRadiotracing) with three-dimensional (3D) histology to dissect the cellular allocation of PET signals in the TME. In mice...
TSPO is a promising novel tracer target for positron-emission tomography (PET) imaging of brain tumors. However, due to the heterogeneity of cell populations that contribute to the TSPO-PET signal, imaging interpretation may be challenging. We therefore evaluated TSPO enrichment/expression in connection with its underlying histopathological and mol...
Various cellular sources hamper interpretation of positron-emission-tomography (PET) biomarkers in the tumor microenvironment (TME). We developed immunomagnetic cell sorting after in vivo radiotracer injection (scRadiotracing) in combination with 3D-histology via tissue clearing to dissect the cellular allocation of PET signals in the TME. In SB28...
OBJECTIVE
The 18 kDa translocator protein (TSPO) is expressed in both activated microglia and glioma cells. Elevated expression of TSPO has been reported to be associated with higher WHO grade. Here we analyze whether TSPO positron emission tomography (PET) signal using the tracer [18F]GE-180 is correlated with clinical outcome in a cohort of patie...
OBJECTIVE
Translocator protein (TSPO) PET imaging is used in different neurological diseases and emerges as new tool for the diagnosis and therapy planning of glioma patients. Various signal sources of the TSPO-PET signal, however, hamper image interpretation and biological understanding. Here we assess the TSPO expression and ligand uptake in a mu...
Glioblastoma combines a lack of immunogenicity with a highly immunosuppressive tumor microenvironment (TME), including both tumor and immune cells. However, biomarkers that allow monitoring of the immune phenotype are still lacking. Hence, we investigated the 18kDa translocator protein (TSPO) during tumor progression in an experiential glioblastoma...
Purpose
Glioma patients, especially recurrent glioma, suffer from a poor prognosis. While advances to classify glioma on a molecular level improved prognostication at initial diagnosis, markers to prognosticate survival in the recurrent situation are still needed. As 18 kDa translocator protein (TSPO) was previously reported to be associated with a...
![[¹⁸F]GE-180 tracer kinetics in SB28 and sham mice. Time-activity-curves...](publication/364398663/figure/fig1/AS:11431281187932875@1694451623777/FGE-180-tracer-kinetics-in-SB28-and-sham-mice-Time-activity-curves-normalized-to_Q320.jpg)
Introduction
The 18 kDa translocator protein (TSPO) receives growing interest as a biomarker in glioblastoma. Mouse models can serve as an important tool for the investigation of biomarkers in glioblastoma, but several glioblastoma models indicated only low TSPO-PET signals in contrast to high TSPO-PET signals of human glioblastoma. Thus, we aimed...
Purpose
Glioma patients, especially recurrent glioma, suffer from a poor prognosis. While advances to classify glioma on a molecular level improved prognostication at initial diagnosis, markers to prognosticate survival in the recurrent situation are still needed. As 18 kDa translocator protein (TSPO) was previously reported to be associated with a...
e14044
Background: Aggressive brain tumors like glioblastoma depend on support by their local environment. While the role of tumor-associated myeloid cells on glioblastoma progression is well-documented, we have only partial knowledge of the pathological impact of glioblastoma -parenchymal progenitor cells. Methods: We investigated the glioblastoma...
Aggressive brain tumors like glioblastoma depend on support by their local environment and subsets of tumor parenchymal cells may promote specific phases of disease progression. We investigated the glioblastoma microenvironment with transgenic lineage-tracing models, intravital imaging, single-cell transcriptomics, immunofluorescence analysis as we...
Pancreatic ductal adenocarcinoma is characterized by a strong immunosuppressive network with a dense infiltration of myeloid cells including myeloid-derived suppressor cells (MDSC). Two distinct populations of MDSC have been defined: polymorphonuclear MDSC (PMN-MDSC) and monocytic MDSC (M-MDSC). Several factors influence the development and functio...
Introduction: With a 5-year overall survival of less than 8 %, pancreatic ductal adenocarcinoma (PDAC) is the fourth most frequent cause of cancer-related deaths worldwide. Moreover, the incidence of PDAC is expected to rise in future as projections indicate a more than two-fold increase of new cases within the next ten years. Two major obstacles s...
Molecular imaging is essential for diagnosis and treatment planning for glioblastoma patients. Positron emission tomography (PET) with tracers for the detection of the solute carrier family 7 member 5 (SLC7A5; also known as the amino acid transporter light chain L system, LAT1) and for the mitochondrial translocator protein (TSPO) is successfully u...
Following publication of the original article [1], the authors have reported that Fig. 2 and Additional file 1: Figure S1, S2 partially show red scripts.
Background:
The tumor microenvironment (TME) combines features of regulatory cytokines and immune cell populations to evade the recognition by the immune system. Myeloid-derived suppressor cells (MDSC) comprise populations of immature myeloid cells in tumor-bearing hosts with a highly immunosuppressive capacity. We could previously identify RIG-I-...
Mit einem Gesamtüberleben von weniger als 5 % der Patienten 5 Jahre nach Erstdiagnose stellt das duktale pankreatische Adenokarzinom (PDAC) eine der prognostisch ungünstigsten Tumorentitäten dar. Hinzu kommt, dass die Inzidenz dieser Tumorentität klar ansteigt. Die Standardbehandlung umfasst die chirurgische Resektion (falls möglich), zumeist gefol...
Checkpoint molecules such as programmed death 1 (PD-1) dampen excessive T cell activation to preserve immune homeostasis. PD-1-specific monoclonal antibodies have revolutionized cancer therapy, as they reverse tumour-induced T cell exhaustion and restore CTL activity. Based on this success, deciphering underlying mechanisms of PD-1-mediated immune...
With an overall survival of less than 5% at 5 years post diagnosis pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating cancer entities. Furthermore, the prevalence of PDAC is assumed to considerably increase in the nearer future. Its standard treatment encompasses surgical resection (if possible), frequently followed by radiochem...
Background and Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a cancer entity with growing prevalence and very poor prognosis. The survival rates are limited to approximately 25% of patients after one year and only 5% after five years, respectively. Standard treatment encompasses surgical resection (if possible) accompanied by radiotherapy, ch...
The RIG-I-like helicase melanoma differentiation-associated protein 5 (MDA5) is an innate immune receptor for double-stranded viral RNA (dsRNA) that induces a type I interferon (IFN)-driven immune response. In the present study, we demonstrate that human und murine pancreatic cancer cells express functional MDA5 and are highly sensitive to MDA5-ind...
Background
Pancreatic cancer shows a dense infiltration of immature myeloid cells including myeloid-derived suppressor cells (MDSCs). In the tumour, MDSCs polarise in alternatively activated M2/G2 cells, suppressing T cell responses. We previously reported that RNA-based immunotherapy with ligands for the cytosolic helicase MDA5 leads to type I int...
Hintergrund: Im Pankreaskarzinom unterhalten myeloide Zellen, wie myeloid-derived suppressor cells (MDSC), ein potentes immunsuppressives Milieu. Man unterscheidet MDSC monozytaren und granulozytaren Ursprungs (M- bzw. G-MDSC), die sich im Tumor in alternativ-aktivierte M2/G2-Zellen differenzieren. Im Gegensatz zu M1/G1-Zellen, die produktive Immun...
Pancreatic cancer is characterized by a microenvironment suppressing immune responses. RIG-I-like helicases (RLH) are immunoreceptors for viral RNA that induce an antiviral response program via the production of type I interferons (IFN) and apoptosis in susceptible cells. We recently identified RLH as therapeutic targets of pancreatic cancer for co...
